Human nature meets technology in MedTech sales

Tern plc

Sales teams are asked to master products that change lives, yet the way they are trained rarely matches the complexity or urgency of the task. The numbers tell a familiar story, long onboarding times, high turnover, and widespread target misses. But beneath the statistics lies a deeper truth: much of what is taught simply does not stick.

The core issue is human nature itself. Our brains are wired to forget what we do not actively apply. Traditional sales education, the manuals, the workshops, the static presentations, leans on outdated methods that assume information can be absorbed through repetition.

The shift now underway is about changing how people learn. Artificial Intelligence, Mixed Reality, and Augmented Reality are converging to create environments where knowledge becomes experience. Instead of reading about a medical device, a sales representative can manipulate it holographically, exploring every function and feature in three dimensions. Instead of rehearsing sales pitches in abstract, they can engage with realistic AI-driven simulations that replicate the tension and unpredictability of real clinical conversations.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Tern Plc publishes presentations from Device Authority and Talking Medicines investor event

Tern Plc has released copies of the presentations delivered by portfolio companies Device Authority and Talking Medicines during its recent online investor presentation and Q&A session.

Tern Plc updates position in Talking Medicines with new convertible loan notes

Tern Plc has received about £230,000 in new unsecured convertible loan notes from Talking Medicines after cancelling around £180,000 of short term loans provided over 2024 and 2025.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

Tern Plc raises £151,000 through Open Offer to shareholders

Tern Plc has successfully raised approximately £151,000 before expenses through its Open Offer, issuing 30.2 million new ordinary shares at 0.50 pence each.

Tern Plc cuts Board pay and introduces shareholder distribution policy

Tern has announced a 50% reduction in fixed remuneration for its Board and executive management from 1 November 2025, expected to save around £153,000 annually. The company has also introduced a new policy linking management pay to investment exits and committed to distributing at least 50% of net proceeds from disposals over £1 million to shareholders, subject to reserves and regulatory requirements.

Tern Plc launches £642k Open Offer at 0.50p per share

Tern Plc has announced an Open Offer to raise up to £642,486 through the issue of 128.5 million new shares at 0.50p each, a 20% discount to the recent market price.

Search

Search